• About
  • Contact
  • Resources
  • Book Nook
Donate
  • Featured
  • Commentary
  • Science & News
  • Mainstream
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Michael Lerner’s Blog
    • Guest Authors
MenuClose
  • Featured
  • Commentary
  • Science & News
  • Mainstream Solutions
    • Mainstream Prevention
    • Mainstream Treatment
    • Vaccines
    • Repurposed Drugs
  • Integrative Therapies
    • Integrative Prevention
    • Integrative Treatments
    • Integrative Recovery
      • Long Haul
  • Controversies
    • Ivermectin
  • Blog
    • Guest Authors
    • Michael Lerner’s Blog
  • About
  • Contact
  • Resources
  • Donate
 — Article Category —

Mainstream Solutions


Time to Stop Using Ineffective Covid-19 Drugs

Time to Stop Using Ineffective Covid-19 Drugs

by Covid Strategies | Aug 18, 2022 | Featured, Ivermectin, Mainstream Treatment, Repurposed Drugs

By Salim S. Abdool Karim, M.B., Ch.B., Ph.D., and Nikita Devnarain, Ph.D. In practicing evidence-based medicine, physicians use the best evidence currently available on safety and efficacy in making decisions on treatment choices for their patients. During the...

read more
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

by Covid Strategies | Aug 18, 2022 | Controversies, Featured, Ivermectin, Mainstream Treatment

By Carolyn T. Bramante, M.D., M.P.H., et al. Abstract BACKGROUND Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic....

read more
FDA allows pharmacists to prescribe Paxlovid COVID treatment

FDA allows pharmacists to prescribe Paxlovid COVID treatment

by Covid Strategies | Jul 6, 2022 | Featured, Mainstream Treatment, Science & News

By Oriana Gonzalez The Food and Drug Administration said Wednesday it's allowing state-authorized pharmacists to prescribe Pfizer's antiviral treatment Paxlovid. Driving the news: It's a win for pharmacies, which had been pushing for the FDA to allow...

read more
What Is ‘Paxlovid Rebound’? CDC Warns of COVID-19 Recurrence After Antiviral Treatment

What Is ‘Paxlovid Rebound’? CDC Warns of COVID-19 Recurrence After Antiviral Treatment

by Covid Strategies | Jun 1, 2022 | Featured, Mainstream Treatment, Science & News

The recurring symptoms are usually milder than the initial illness—but you may still be contagious. By Julia Ries  Some patients who have taken Pfizer's Paxlovid medication—an antiviral drug used to prevent severe illness from COVID-19—have experienced a recurrence in...

read more
Rebound COVID Is Just the Start of Paxlovid’s Mysteries

Rebound COVID Is Just the Start of Paxlovid’s Mysteries

by Covid Strategies | May 26, 2022 | Featured, Mainstream Treatment

There’s plenty more to learn about the lifesaving antiviral COVID treatment.   By Rachel Gutman The first data on Paxlovid, out last November, hinted that the COVID antiviral would cut the risk of hospitalization and death by 89 percent. Pundits called the drug...

read more
FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return

FDA rebukes Pfizer CEO’s suggestion to take more Paxlovid if COVID-19 symptoms return

by Covid Strategies | May 5, 2022 | Featured, Mainstream Treatment, Science & News

By Zoey Becker The FDA rebuked Pfizer CEO Albert Bourla’s proposed solution to reports that some patients experienced a relapse of COVID-19 symptoms after treatment with the company's antiviral Paxlovid. After reports said some patients who took Paxlovid rebounded and...

read more
FAMOTIDINE SHOWN TO SIGNIFICANTLY DECREASE COVID SYMPTOMS IN 55-PATIENT RANDOMIZED TRIAL

FAMOTIDINE SHOWN TO SIGNIFICANTLY DECREASE COVID SYMPTOMS IN 55-PATIENT RANDOMIZED TRIAL

by Covid Strategies | Feb 26, 2022 | Featured, Repurposed Drugs

Famotidine, the over-the-counter heartburn drug, pepcid, was shown to significantly decrease COVID symptoms in a 55-patient randomized trial authored by Dr. Tobias Janowitz and published in the BMJ journal Gut February 10, 2022. Famotidine has been...

read more
Honduras Reduced COVID Deaths With Repurposed Drugs, Early Treatment

Honduras Reduced COVID Deaths With Repurposed Drugs, Early Treatment

by Covid Strategies | Feb 11, 2022 | Repurposed Drugs, Science & News

Dr. Fernando Valerio, a critical care doctor in Honduras who co-authored a recent peer-reviewed study indicating the potential of repurposed drugs targeting SARS-CoV-2, shared with Trial Site his experience treating patients in the Central American nation....

read more
Concern as Republicans push to make dubious Covid cure prescriptions easier

Concern as Republicans push to make dubious Covid cure prescriptions easier

by Covid Strategies | Jan 30, 2022 | Controversies, Featured, Ivermectin, Repurposed Drugs

Ivermectin and hydroxychloroquine, the cures in question, have proven to be ineffective in preventing or treating Covid-19 By Eric Berger Republican state lawmakers across the United States have proposed – and in some cases passed – legislation that they say keeps the...

read more
NIAID Sponsored Study: Hyperimmune Intravenous Immunoglobulin & Remdesivir Fails to Beat Remdesivir as COVID-19 Treatment

NIAID Sponsored Study: Hyperimmune Intravenous Immunoglobulin & Remdesivir Fails to Beat Remdesivir as COVID-19 Treatment

by Covid Strategies | Jan 29, 2022 | Mainstream Treatment, Science & News

Recently, an international trial site network known as the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) completed a global study revealing that remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2...

read more
TFF Pharmaceuticals Advancing Niclosamide, an Inhaled COVID-19 Treatment with Potential Activity Against Multiple Variants

TFF Pharmaceuticals Advancing Niclosamide, an Inhaled COVID-19 Treatment with Potential Activity Against Multiple Variants

by Covid Strategies | Jan 28, 2022 | Mainstream Treatment, Science & News

TFF Pharmaceuticals announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other respiratory viral diseases. TFF develops...

read more
Paxlovid Cleared for Conditional Use in Europe

Paxlovid Cleared for Conditional Use in Europe

by Covid Strategies | Jan 27, 2022 | Mainstream Treatment, Science & News

Paxlovid, the oral Pfizer treatment for COVID-19, appears headed for emergency use authorization in Europe.  Conditional Marketing Authorization for Paxlovid The European Medical Agency’s (EMA) human medicines committee (CHMP) recommended Pfizer Europe MA EEIG...

read more
University of Calgary Repurposed Drug Breakthrough: Hydroxychloroquine Delays Severe Forms of Multiple Sclerosis

University of Calgary Repurposed Drug Breakthrough: Hydroxychloroquine Delays Severe Forms of Multiple Sclerosis

by Covid Strategies | Jan 24, 2022 | Repurposed Drugs, Science & News

What if a relatively low-cost, repurposed drug could help treat multiple sclerosis (MS), the least treatable of all autoimmune diseases? That could be a distinct possibility now that Dr. Marcus Koch, MD, Ph.D., and Dr. Wee Yong, Ph.D., with Cummings School of Medicine...

read more
Merck Inks Deal with Bangladeshi Pharma to Distribute Molnupiravir to 100+ Countries Targeting Important COVID-19 Antiviral Market

Merck Inks Deal with Bangladeshi Pharma to Distribute Molnupiravir to 100+ Countries Targeting Important COVID-19 Antiviral Market

by Covid Strategies | Jan 23, 2022 | Repurposed Drugs, Science & News

With a great demand for antivirals targeting early-onset COVID-19, Merck inked a sub-licensing deal with one of the largest pharmaceutical companies in Bangladesh to produce Molnupiravir (Lagevrio) for distribution to over 100 nations. The deal, part of the Medicine...

read more
Merck’s COVID-19 pill to be produced by more than two dozen drugmakers

Merck’s COVID-19 pill to be produced by more than two dozen drugmakers

by Covid Strategies | Jan 20, 2022 | Featured, Mainstream Solutions, Mainstream Treatment

BY MONIQUE BEALS Medicines Patent Pool, an organization supported by the U.N., announced on Thursday that over two dozen generic drug makers will soon begin producing Merck's COVID-19 pill to make the treatment more accessible in developing...

read more
Page 1 of 3012345…102030…»Last »

Address:

Commonweal P.O Box 316 | Bolinas, CA 94924

Latest Covid news in your inbox!

Success!

Subscribe

Search Articles

©2021 CovidStrategies/Commonweal | Site maintained by Mercury Multimedia

Privacy Policy | Home